4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis-Reference-Cited by-同舟云学术

4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis

Published:2013-10 Issue: Volume:248 Page:62-71
ISSN:0014-4886
Container-title:Experimental Neurology
language:en
Short-container-title:Experimental Neurology

Author:

Göbel Kerstin,Wedell Jan-Hendrik,Herrmann Alexander M.,Wachsmuth Lydia,Pankratz Susann,Bittner Stefan,Budde Thomas,Kleinschnitz Christoph,Faber Cornelius,Wiendl Heinz,Meuth Sven G.

Funder

DFG

Interdisciplinary Center for Clinical Research (IZKF) Münster

Else-Kröner-Fresenius-Foundation (EKFS)

Biogen Idec

Publisher

Elsevier BV

Subject

Developmental Neuroscience,Neurology

Reference38 articles.

1. TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system;Bittner;Brain,2009

2. From the background to the spotlight: TASK channels in pathological conditions;Bittner;Brain Pathol.,2010

3. Mechanism of 4-aminopyridine action on voltage-gated potassium channels in lymphocytes;Choquet;J. Gen. Physiol.,1992

4. Molecular diversity of K+ channels;Coetzee;Ann. N. Y. Acad. Sci.,1999

5. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis;Dunn;Curr. Med. Res. Opin.,2011

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neuron-oligodendrocyte potassium shuttling at nodes of Ranvier protects against inflammatory demyelination;Journal of Clinical Investigation;2023-04-03

2. Sexual function and fertility preservation in testicular cancer survivors;Journal of Men's Health;2023

3. Using an animal model to predict the effective human dose for oral multiple sclerosis drugs;Clinical and Translational Science;2022-11-23

4. Ion Channels as New Attractive Targets to Improve Re-Myelination Processes in the Brain;International Journal of Molecular Sciences;2021-07-06

5. Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020;Drugs;2021-06